Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06815471 · ClinicalTrials.gov registry record · Phase 2
CRF2 Agonist for the Treatment of Worsening Heart Failure
A Phase 2 study of Worsening Heart Failure, sponsored by Corteria Pharmaceuticals.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 300
- Enrollment target
- 20
- Study locations
NCT06815471 is a Phase 2 study of Worsening Heart Failure that is actively recruiting participants, run by Corteria Pharmaceuticals. The registered enrollment target is 300 participants. The trial reports 20 study locations across 6 states.
The verdict
NCT06815471, a Phase 2 study of Worsening Heart Failure, is actively recruiting participants, sponsored by Corteria Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 300 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG COR-1167
Study Locations (20)
Other
- Sdružené zdravotnické zařízení Krnov - Krnov
- Nemocnice Slaný - Slaný
- Aleksandre Aladashvili Clinic LLC - Tbilisi
- LTD "Israeli-Georgian Medical Research Clinic Healthycore" - Tbilisi
- Acad. G. Chapidze Emergency Cardiology Center LTD, Department of Internal Medicine and Medical Research - Tbilisi
- Acad. G.Chapidze Emergency Cardiology Center, LTD, Department of Multi-center Clinical Trials - Tbilisi
- Bokhua Memorial Cardiovascular Center LTD - Tbilisi
- St. Michael's Hospital LLC - Tbilisi
- Tbilisi Heart and Vascular Clinic, LTD - Tbilisi
- Georgian Dutch Hospital - Tbilisi
- LTD Tbilisi Heart Center - Tbilisi
- Semmelweis Egyetem, Általános Orvostudományi Kar, Városmajori Szív- és Érgyógyászati Klinika - Budapest
- Budapesti Uzsoki Utcai Kórház, Kardiológia Osztály - Budapest
- Pécsi Tudományegyetem, Klinikai Központ, I. sz. Belgyógyászati Klinika - Pécs
North Carolina
- Cone Health Moses Cone Hospital - Greensboro
- NC Heart and Vascular Research, LLC - Raleigh
Indiana
- Indiana University Health Methodist Hospital - Indianapolis
Ohio
- Ohio State University - Columbus
Oklahoma
- South Oklahoma Heart Research, LLC - Oklahoma City
Czech Republic
- Fakultní nemocnice Ostrava - Ostrava
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2026-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06815471
The ClinicalTrials.gov registry entry for NCT06815471 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Corteria Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Worsening Heart Failure appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06815471 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Other, North Carolina, Indiana.
Frequently Asked Questions
What is clinical trial NCT06815471 about?
NCT06815471 is a clinical study titled "CRF2 Agonist for the Treatment of Worsening Heart Failure". This study assesses the effects of the investigational drug COR-1167 in subjects hospitalised due to worsening of heart failure (HF)
What is the current status of trial NCT06815471?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 300 participants. The study started on 2025-08-07. Estimated completion is 2026-12.
What conditions does trial NCT06815471 study?
This clinical trial studies the following conditions: Worsening Heart Failure.
What interventions are being tested in trial NCT06815471?
The interventions under investigation include: Placebo (DRUG), COR-1167 (DRUG).
Who is sponsoring clinical trial NCT06815471?
This trial is sponsored by Corteria Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06815471 being conducted?
This trial has 20 study locations across Indiana, North Carolina, Ohio, Oklahoma, Czech Republic. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.